Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Has reproduction · 79
Epigenetic loss of heterogeneity from low to high grade localized prostate tumours.
PMID 34911933 · PMC8674326 · Nature communications · 2021 · 7 claims · 4 setups
Shared chromatin accessibility features among low-grade (Gleason pattern 3) prostate cancer cells are lost in high-grade (Gleason pattern 4) tumours.
-
Has reproduction · 70
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
PMID 36450752 · PMC9712620 · Nature communications · 2022 · 8 claims · 8 setups
AR enhancer/chromatin binding usage is highly heterogeneous between primary prostate tumors, with <5% of all AR binding sites shared by half of tumors analyzed.
-
Has reproduction · 80
Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA.
PMID 22466171 · PMC3371705 · Genome research · 2012 · 8 claims · 8 setups
BisChIP-seq — bisulfite sequencing of chromatin immunoprecipitated DNA — enables direct genome-wide, base-resolution interrogation of DNA methylation on histone-modified DNA molecules
-
Full-text index only
Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.
PMID 19763266 · PMC2740864 · PloS one · 2009 · 8 claims · 8 setups
Androgen treatment alters the whole-cell proteome of LNCaP prostate cancer cells
-
Has reproduction · 69
Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.
PMID 39183332 · PMC11345443 · Cell death & disease · 2024 · 8 claims · 8 setups
Pax5 is a transcription factor specifically expressed in t-NEPC/NE-like prostate cancer and drives neuronal gene expression characteristic of this subtype.